Saturday, March 2, 2024

CATEGORY

Eli Lilly

Lilly Introduces LillyDirect Telehealth Services for Obesity and Additional Medications

Eli Lilly, a prominent pharmaceutical company, has recently introduced a new website-based access program called LillyDirect, marking a significant shift in the way certain...

FDA Grants Approval to Eli Lilly’s Omvoh for Ulcerative Colitis Treatment

After an initial rejection, the FDA approved Eli Lilly's groundbreaking IL-23p19 inhibitor, mirikizumab, as a treatment for adults dealing with moderately to severely active...

Zepbound: Eli Lilly’s New Weight Loss Drug to Challenge Novo Nordisk’s Wegovy with Competitive Pricing

Eli Lilly's weight loss drug, Zepbound, has been recently approved by the FDA and is positioned to compete with Novo Nordisk's Wegovy. In a...

Eli Lilly’s Tirzepatide Gets FDA Nod for Obesity Treatment as Zepbound

Eli Lilly’s drug tirzepatide, known as Mounjaro for type 2 diabetes, has recently received FDA approval for obesity treatment under the brand name Zepbound....

Eli Lilly’s Zepbound Approved by FDA as Rival Weight-Loss Drug to Novo Nordisk’s Wegovy

Eli Lilly has received FDA approval for its therapy tirzepatide, now known as Zepbound, as a weight-loss drug. This development introduces major competition to...

Eli Lilly, Novo Nordisk, Moderna and Regeneron Post Strong Quarterly Earnings Owing to Successful Development Initiatives

Eli Lilly, Novo Nordisk, Moderna, and Regeneron achieved robust quarterly earnings, attributing it to the success of their drug and pipeline development initiatives. Eli...

Eli Lilly Faces FDA Delay for Lebrikizumab Designed for Treating Atopic Dermatitis Due to Manufacturing Issues

Eli Lilly's plans for a swift FDA approval of lebrikizumab, its IL-13 inhibitor designed for treating atopic dermatitis (eczema), have been thwarted by problems...

Latest news

Sticky Image